Recent advances in the diagnosis and treatment of deep vein thrombosis: A regional consensus

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 309-315

  Qari, Mohamad ^a   Abdel Razeq, Hikmat ^b   Alzeer, Abdulaziz ^c   Alizadeh, Hussein ^d   Kristensen, Jorgen ^d   Al Sayegh, Faisal ^e   Qutub, Hatem ^f   Marashi, Mahmoud ^g   Husted, Steen ^h   Mousa, Shaker ⁱ  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b King Fahd Armed Force Hospital   (Saudi Arabia)

^c The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^d TAWAM HOSPITAL   (United Arab Emirates)

^e KUWAIT UNIVERSITY   (Kuwait)

^f Dammam Hospitals   (Saudi Arabia)

^g RASHID HOSPITAL   (United Arab Emirates)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anti factor IIa; Anti factor Xa; Coagulation; Diagnosis; DVT; Embolism; LMWH; PE; Therapy; Thrombolysis; Thrombophilia; Thrombosis; Warfarin

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; SEX HORMONE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; GENE MUTATION; GENETIC DISORDER; HEALTH CARE COST; HUMAN; HYPERCOAGULABILITY; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARD; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VENA CAVA FILTER; VERTEBRA FRACTURE;

ANTICOAGULANTS; FEMALE; HEMOSTASIS; HEPARIN; HUMANS; NEOPLASMS; PREGNANCY; RISK FACTORS; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 0038755134     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP: A prospective study of venous thromboembolism after major trauma. N Engl J Med (1994) 331(24):1601-1606.
2. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA: A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med (1996) 335(10):701-707.
3. Clagett GP: Prevention of postoperative venous thromboembolism: An update. Am J Surg (1994) 168(6):515-522.
4. Andersen BS, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J: The cumulative incidence of venous thromboembolism during pregnancy and puerperium - An 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand (1998) 77(2):170-173.
5. Lindqvist P, Dahlback B, Marsal K: Thrombotic risk during pregnancy: A population study. Obstet Gynecol (1999) 94(4):595-599.
6. Ray JG, Chan WS: Deep vein thrombosis during pregnancy and the puerperium: A meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv (1999) 54(4):265-271.
7. Gerstmann BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol (1991) 133(1):32-37.
8. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP: Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemost (1997) 78(1):327-333.
9. WHO Study Group: Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet (1995) 346:1582-1588.
10. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD: Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J (1996) 312(7023):83-88.
11. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet (1997) 349(9045):83-88.
12. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med (1992) 232(2):155-160.
13. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH: Age-specific incidence rates of venous thromboembolism among heterozygous carriers of Factor V Leiden mutation. Ann Intern Med (1997) 126(7):528-531.
14. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ: Cancer and venous thromboembolism. Am Heart J (1996) 132(4):850-855.
15. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J: Antiphospholipid antibodies and venous thromboembolism. Blood (1995) 86(10):3685-3691.
16. Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A: Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost (1996) 76(2):187-189.
17. Finazzi G, Barbui T: Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost (1994) 71(1):15-18.
18. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA: Thrombosis in antithrombin III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 116(9):754-761.
19. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW: Prevalence of antithrombin deficiency in the healthy population. Br J Haematol (1994) 87(1):106-112.
20. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM: Prevalence of protein C deficiency in the healthy population. Thromb Haemost (1995) 73(1):87-93.
21. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 68(5):1370-1373.
22. Broekmans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 309(6):340-344.
23. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH: Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 64(6):1297-1300.
24. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, Prandoni P, Bura A, Rejto L, Wells P, Mannucci PM et al: The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood (1999) 94(11):3702-3706.
25. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van Der Velden PA, Reitsman PH: Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature (1994) 369(6475):64-67.
26. Rees DC, Cox M, Clegg JB: World distribution of Factor V Leiden. Lancet (1995) 346(8983):1133-1134.
27. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med (1994) 330(8):517-522.
28. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1993) 342(8886-8887):1503-1506.
29. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for Factor V Leiden (activated protein C resistance). Blood (1995) 85(6):1504-1508.
30. Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K et al: Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol (1998) 18(8):1287-1291.
31. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE et al: Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost (1998) 79(4):706-708.
32. Hillarp A, Zoller B, Svensson PJ, Dahlback B: The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost (1997) 78(3):990-992.
33. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D: Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost (1998) 80(1):49-51.
34. Margaglione M, Brancaccio V, Guiliani N, D'Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G: Increased risk for venous thrombosis in carriers of the prothrombin G → A20210 gene variant. Ann Intern Med (1998) 129(2):89-93.
35. Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost (1999) 81(2):165-176.
36. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb (1994) 14(7):1080-1083.
37. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ: Interrelation of hyperhomocyst(e)inemia, Factor V Leiden, and the risk of future venous thromboembolism. Circulation (1997) 95(7):1777-1782.
38. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor an occurrence of deep-vein thrombosis. Lancet (1995) 345(8943):152-155.
39. Kraaijenhagen RA, In't Anker PS, Koopman MM, Reitsma PH, Prins MH, Van Den Ende A, Buller HR: High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 83(1):5-9.
40. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S: High plasma levels of Factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 343(7):457-462.
41. Van Hylckama VA, Van Der Linden IK, Bertina RM, Ronsendaal FR: High levels of Factor IX increase the risk of venous thrombosis. Blood (2000) 95(12):3678-3682.
42. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR: High levels of coagulation Factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 343(10):696-701.
43. Zoller B, Svensson PJ, He X, Dahlback B: Identification of the same Factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest (1994) 94(6):2521-2524.
44. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM: A Factor V genetic component differing from Factor V R506Q contributed to the activated protein C resistance phenotype. Blood (1997) 90(4):1552-1557.
45. 306 → Thr) associated with resistance to activated protein C. Blood (1998) 91(4):1140-1144.
46. Wells PS, Anderson DR, Bormani J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B: Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet (1997) 350(9094):1795-1798.
47. Bigaroni A, Perrier A, Bounameaux H: Is clinical probability assessment of deep vein thrombosis by a score really standardized? Thromb Haemost (2000) 83(5):788-789.
48. Cogo A, Lensing AWA, Koopman MMW, Piovella F, Siragusa S, Wells PS, Villalta S, Buller HR, Turpie AGG, Prandoni P: Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: Prospective cohort study. Br Med J (1998) 316(7124):17-20.
49. Perrier A, Desmarais S, Miron MJ, De Moerloose P, Lepage R, Slosman D, Didier D, Unger PF, Patenaude JV, Bounameux H: Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet (1999) 353(9148):190-195.
50. Becker DM, Phibrick JT, Bachhuber TL, Humphries JE: D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? Arch Intern Med (1996) 156(9):939-946.
51. Janssen MC, Wollersheim H, Verbruggen B, Novakova IR: Rapid D-dimer assays to exclude deep venous thrombosis and pulmonary embolism: Current status and new developments. Semin Thromb Haemost (1998) 24(4):393-400.
52. Borg JY, Levesque H, Cailleux N, Franc C, Hellot MF, Courtois H: Rapid quantitative D-dimer assay and clinical evaluation for the diagnosis of clinical suspected deep vein thrombosis. Thromb Haemost (1997) 77(3):602-603.
53. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, Martorell A: Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer (1991) 67(2):541-545.
54. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med (1996) 125(10):785-793.
55. Heittiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P: Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis. Cancer (1998) 83(1):180-185.
56. Sorensen HT, Mellemkjaer L, Steffenssen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med (1998) 338(17):1169-1173. In this study, patients diagnosed with DVT or PE were identified from the Danish National Registry between 1977 through 1992 (15,348 patients with DVT and 11,305 patients with PE). A total of 1737 cases of cancer were identified in the DVT group compared with 1372 expected cases, and similar findings were reporte for patients with PE. The risk ratio was substantially elevated only during the first 6 months of follow-up and declined rapidly thereafter to a constant level just above 1.0.
57. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, Ten Cate JW: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 327(16):1128-1133.
58. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S: The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized controlled trial. Ann Intern Med (1993) 119(9):874-881.
59. De Groot MR, Büller HR, Ten Cate JW, Van Marwijk Kooy M: Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital. Thromb Haemost (1998) 80(1):70-73.
60. Campbell NRC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE: Aging and heparin-related bleeding. Arch Intern Med (1996) 156(8):857-860.
61. Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, Van Der Meer FJ, Huisman MV: Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: A study in routine clinical practice. Arch Intern Med (2000) 160(15):2369-2373.
62. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S: Heparin-induced thrombocytopenia with thrombosis: Incidence analysis of risk factors and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol (1997) 56(1):12-16.
63. Weitz JI: Low-molecular-weight heparins. N Engl J Med (1997) 337(10):688-698.
64. Merli G, Spiro TE, Olsson GC, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA et al: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolitic disease. Ann Intern Med (2001) 134(3):191-200. In this study, 900 patients with symptomatic lower extremity DVT (32% also had confirmed PE), were randomized to three treatment arms. The first received UFH infusion, while the second and third group received subcutaneous enoxaparin sodium at two different doses (1.5 mg/kg once daily or 1.0 mg/kg twice daily), along with warfarin therapy. After 3-months of follow-up, symptomatic VTE recurred in 4.1% of the UFH group, 4.4% of the once-daily enoxaparin sodium group and only 2.9% in the group receiving enoxaparin sodium twice-daily. Incidence of major hemorrhage did not direct among the three treatment groups.
65. The Columbus Investigators: Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med (1997) 337(10):657-662.
66. Breddin HK, Hack-Wunderle V, Nakov R, Kakkar V: Effect of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Eng J Med (2001) 344(9):626-631. In this study, 1021 patients with symptomatic VTE (one third had PE) were randomized to fixed dose subcutaneous reviparin sodium (a second generation LMWH) or adjusted dose intravenous UFH. All patients also received coumarin derivative for 12 weeks. At 12 weeks, 5.3% of patients assigned to reviparin sodium had recurrent thromboembolism compared with 4.9% in the UFH. No difference in major bleeding between the two treatment arms occurred. This study confirmed that LMWH is effective and safe as adjusted-dose UFH.
67. Lensing AWA, Prins MH, Davidson BL, Hirsh J: Treatment of deep venous thrombosis with low-molecular-weight heparin: A meta-analysis. Arch Intern Med (1995) 155(6):601-607.
68. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med (1996) 100(3):269-277.
69. Leizorovicz A, Simonneau G, Decousus H, Boissel JP: Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: A meta-analysis. Br Med J (1994) 309(6950):299-304.
70. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG: Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 119(1 Suppl): 176S-193S. This review is part of the Sixth American College of Chest Physician Consensus Conference on Antithrombotic Therapy.
71. Dahlman TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol (1993) 168(4):1265-1270.
72. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P: The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost (1996) 75(2):254-257.
73. Monreal M, Lafoz E, Olive A, Del Rio L, Vedia C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost (1994) 71(1):7-11.
74. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG: A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood (1997) 89(9):3236-3242.
75. Orme ML, Lewis PJ, De Swiet M, Serlin MJ, Sibeon R, Baty JD, Breckenridge AM: May mothers given warfarin breast-feed their infants? Br Med J (1977) 1(6076):1564-1565.
76. McKenna R, Cole ER, Vasan U: Is warfarin sodium contraindicated in the lactating mother? J Pediatr (1983) 103(2):325-327.
77. Goldhaber SZ, Meyerovits MF, Green D, Vogelzang RL, Citrin P, Heit J: Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med (1990) 88(3):235-240.
78. Turpie AGG, Levine M, Hirsh J, Ginsberg JS, Cruikshank M, Jay R, Gent M: Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest (1990) 97(Suppl 4):172-175.
79. Arnesen H, Hoiseth A, Ly B: Streptokinase or heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. Acta Med Scand (1982) 211(1-2):65-68.
80. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 125(1):1-7.
81. Schwieder G, Grimm W, Siemens H, Flor B, Hilden A, Gmelin E, Friedrich HJ, Wagner T: Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT) - A German multicenter trial. Thromb Haemost (1995) 74(5):1240-1243.
82. Grossman C, McPherson S: Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. Am J Roentgenol (1999) 172(3):667-672.
83. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH: Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology (1999) 211(1):39-49.
84. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M: Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg (2000) 32(1):130-137.
85. Tarry WC, Makhoul RG, Tisnado J, Posner MP, Sober M, Lee HM: Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis. Ann Vasc Surg (1994) 8(6):583-590.
86. Stewart JR, Greenfield LJ: Transvenous vena caval filtration and pulmonary embolectomy. Surg Clin North Am (1982) 62(3):411-430.
87. Linsenmaier U, Rieger J, Schenk F, Rock C, Mangel E, Pfeifer KJ: Indications, management, and complications of temporary inferior vena cava filters. Cardiovasc Intervent Radiol (1998) 21(6):464-469.
88. Dorfman GS: Percutaneous inferior vena caval filters. Radiology (1990) 174(3 Pt 2):987-992.
89. Meyer G, Tamisier D, Sors H, Stern M, Vouhe P, Makowski S, Neveux JY, Leca F, Even P: Pulmonary embolectomy: A 20-year experience at one center. Ann Thorac Surg (1991) 51(2):232-236.
90. Clarke DB, Abrams LD: Pulmonary embolectomy: A 25-year experience. J Thorac Cardiovasc Surg (1986) 92(3 Pt 1):442-445.
91. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 338(7):409-415. In this randomized and prospective study, 400 patients with proximal DVT, who were at high risk of pulmonary embolism, were randomized to receive vena caval filter or no filter. Al patients received UFH or LMWH. At day 12, the incidence of PE was 1.1% in the group who received filter versus 4.8% for the group who had no filter placed. At two years, 20.8% of the group with the filter had a recurrence of DVT compared with only 11.6% for the no-filter group. This study confirmed that the initial benefit achieved was counter-balanced by the excess in DVT recurrence.